title: Enhanced clot dissolution in vitro by 1.8-MHz pulsed ultrasound.
abstract: Clinical studies of acute stroke patients have shown that the use of high frequency, low energy transcranial "diagnostic" ultrasound (US) enhances thrombolysis (sonothrombolysis). In contrast, a previous in vitro study using a clot preparation with coagulation induced by recalcification failed to reproduce an effect of "diagnostic" transcranial US on thrombolysis. We sought to evaluate this contradiction in an in vitro model with modified clot preparation. The efficacy of 1.8-MHz pulsed-wave (PW) ultrasound (US) emitted by a commercial probe on thrombolysis was tested. Whole blood clots from 0.5-mL venous blood samples were insonated for 1 h through a human temporal bone, using 1.8-MHz PW US emitted by a diagnostic device. The experiment was performed with or without recombinant tissue-type plasminogen activator (rt-PA) at a concentration of 10 microg/mL. Thrombolysis was measured by means of clot weight loss after 1 h of insonation. A reduction in thrombus weight occurred when US was used in combination with rt-PA, compared with rt-PA alone (78.7% +/- 2.1% versus 70.8% +/- 4.1%, p <or= 0.0001). Repetition of the experiment produced identical results (76.9% +/- 2.5%, compared with control, p = 0.001). Even without rt-PA, US was effective (41.0% +/- 1.7% versus 36.7% +/- 3.7%, p = 0.04). The results of this in vitro study support the clinical observation that diagnostic transcranial US, with or without rt-PA, enhances thrombolysis.
authors.affiliation: Department of Neurology of Asklepios Hospital North, Hamburg, Germany. juergeneggers@gmx.net
authors.forename: Jürgen
authors.initials: J
authors.lastname: Eggers
authors.forename: Stefan
authors.initials: S
authors.lastname: Ossadnik
authors.forename: Günter
authors.initials: G
authors.lastname: Seidel
mesh_terms: D003131:Combined Modality Therapy; D006801:Humans; D020767:Intracranial Thrombosis / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D020768:Middle Cerebral Artery / Q000473:pathology*; D008953:Models, Anatomic; D011994:Recombinant Proteins / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014464:Ultrasonic Therapy / Q000379:methods*; D017585:Ultrasonography, Doppler, Transcranial
chemical_list: D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator